SCHEMBL17615420

SCHEMBL17615420

O=Cc1c(O)ccc2c3c(c(=O)oc12)CCCCC3

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 11/20 0.68
KDM4E B2RXH2 5/20 0.63
ALDH1A1 P00352 5/20 0.63
GLA P06280 5/20 0.63
GAA P10253 5/20 0.63
HPGD P15428 5/20 0.63
MAOA P21397 2/20 0.63
CASP1 P29466 2/20 0.63
CASP7 P55210 2/20 0.63
HSD17B10 Q99714 2/20 0.63
MAPK1 P28482 1/20 0.63
MAOB P27338 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
USP2 O75604 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.54
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17615429 1.00 ERN1 (0.68) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL17615419 0.99 ERN1 (0.70) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL17618267 0.81 ERN1 (1.00) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL3789883 0.80 KDM4E (0.72) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL17601922 0.79 ERN1 (1.00) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL31454897 0.77 ALDH1A1 (0.63) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL17601914 0.76 ERN1 (1.00) ERN1KDM4EALDH1A1GLAGAA
SCHEMBL16198053 0.76 ERN1 (0.86) ERN1
SCHEMBL10790707 0.76 KDM4E (0.61) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL17615426 0.76 ERN1 (0.82) ERN1KDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 ERN1 3/4885KDM4E 3704/4885ALDH1A1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.